Latest News from Origin
Trade sale exit: Rotageek
Rotageek uses data analytics and AI to optimise workforce scheduling. We invested at a very early stage, in 2018. Since then, founder Chris McCulloch and his team have built a business that is at the forefront of its sector. The company commenced an exit process in late 2024, culminating in a very successful sale in May this year. We thank Chris and the team for their enormous efforts over an extended period, and wish them all the best for the future. Read more here.
Unum – follow-on investment
We are delighted to have lead a follow-on funding round into our Unum, an existing portfolio company producing business class aircraft seating for the new-build (“linefit”) and retrofit markets. Unum has received strong customer interest since our February 2023 investment, and has recently moved to substantial new premises in the Crawley area. This will allow the company to access the local pool of experienced aviation industry professionals and provide the space required to fulfil orders anticipated in 2024 and beyond.
ViaNautis Bio – $25m investment round
Existing Origin portfolio company ViaNautis Bio (formerly SomaServe) has secured $25m in additional finance to further develop and commercialise therapies exploiting its proprietary polyNaut® drug delivery platform. The round was lead by new institutional and corporate venture investors but included significant participation from existing shareholders, including Origin.
Read more here.
